JP2018532382A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532382A5
JP2018532382A5 JP2018511114A JP2018511114A JP2018532382A5 JP 2018532382 A5 JP2018532382 A5 JP 2018532382A5 JP 2018511114 A JP2018511114 A JP 2018511114A JP 2018511114 A JP2018511114 A JP 2018511114A JP 2018532382 A5 JP2018532382 A5 JP 2018532382A5
Authority
JP
Japan
Prior art keywords
peptide
cell
seq
antigen
recognizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532382A (ja
JP6970974B2 (ja
Filing date
Publication date
Priority claimed from GBGB1515321.6A external-priority patent/GB201515321D0/en
Application filed filed Critical
Publication of JP2018532382A publication Critical patent/JP2018532382A/ja
Publication of JP2018532382A5 publication Critical patent/JP2018532382A5/ja
Priority to JP2021072989A priority Critical patent/JP7506026B2/ja
Application granted granted Critical
Publication of JP6970974B2 publication Critical patent/JP6970974B2/ja
Priority to JP2024095596A priority patent/JP2024123066A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511114A 2015-08-28 2016-08-26 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ Active JP6970974B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021072989A JP7506026B2 (ja) 2015-08-28 2021-04-23 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
JP2024095596A JP2024123066A (ja) 2015-08-28 2024-06-13 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211276P 2015-08-28 2015-08-28
GB1515321.6 2015-08-28
GBGB1515321.6A GB201515321D0 (en) 2015-08-28 2015-08-28 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US62/211,276 2015-08-28
PCT/EP2016/070146 WO2017036936A1 (en) 2015-08-28 2016-08-26 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018142058A Division JP6742370B2 (ja) 2015-08-28 2018-07-30 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
JP2021072989A Division JP7506026B2 (ja) 2015-08-28 2021-04-23 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ

Publications (3)

Publication Number Publication Date
JP2018532382A JP2018532382A (ja) 2018-11-08
JP2018532382A5 true JP2018532382A5 (enExample) 2019-10-03
JP6970974B2 JP6970974B2 (ja) 2021-11-24

Family

ID=54326487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511114A Active JP6970974B2 (ja) 2015-08-28 2016-08-26 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
JP2021072989A Active JP7506026B2 (ja) 2015-08-28 2021-04-23 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021072989A Active JP7506026B2 (ja) 2015-08-28 2021-04-23 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ

Country Status (18)

Country Link
US (7) US10525114B2 (enExample)
EP (2) EP3341014A1 (enExample)
JP (2) JP6970974B2 (enExample)
KR (3) KR102308798B1 (enExample)
CN (1) CN107921111B (enExample)
AU (3) AU2016313684B2 (enExample)
BR (1) BR112018003460A2 (enExample)
CA (2) CA3072922A1 (enExample)
CR (6) CR20180423A (enExample)
EA (2) EA201890560A1 (enExample)
GB (1) GB201515321D0 (enExample)
MA (7) MA43459A1 (enExample)
MX (1) MX2018002480A (enExample)
PE (2) PE20181517A1 (enExample)
SG (3) SG10202001831SA (enExample)
TW (15) TWI722662B (enExample)
UA (1) UA124577C2 (enExample)
WO (1) WO2017036936A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN108250286B (zh) * 2016-12-28 2021-06-08 香雪生命科学技术（广东）有限公司 源自于pasd1的肿瘤抗原短肽
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
CR20190509A (es) 2017-04-10 2020-01-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
HUE061502T2 (hu) * 2017-09-28 2023-07-28 Immpact Bio Ltd Univerzális platform gátló kiméra antigén receptor (ICAR) elõállítására
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN109467596B (zh) * 2018-11-12 2021-11-09 湖北省农业科学院畜牧兽医研究所 转录因子sp1在调控猪rtl1基因表达中的应用
CN109738929B (zh) * 2018-12-03 2022-10-21 中国辐射防护研究院 一种基于居民食物最大消费量的剂量估算方法及系统
TWI858016B (zh) * 2019-02-18 2024-10-11 日商肽夢想股份有限公司 血球凝集素結合肽
JPWO2020230792A1 (enExample) * 2019-05-13 2020-11-19
CN110123453B (zh) * 2019-05-31 2021-07-23 东北大学 一种基于无标记增强现实的手术导航系统
EP4136100A4 (en) * 2020-04-14 2024-08-07 Université de Montréal Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof
CN111910000B (zh) * 2020-07-02 2022-07-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统
CA3217185A1 (en) * 2021-04-19 2022-10-27 Board Of Regents, The University Of Texas Systems Methods and compositions comprising mhc class i peptides
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院（北京大学第三临床医学院） 一种用于调节杀伤性t细胞活性的方法、药物及其应用
WO2025015234A2 (en) * 2023-07-13 2025-01-16 Ltz Therapeutics Inc. Multispecific antibodies and uses thereof
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用
CN120183512B (zh) * 2025-05-23 2025-08-12 浙江省肿瘤医院 基于转录组测序构建的用于诊断早期宫颈癌淋巴结转移的方法、模型
CN120908452B (zh) * 2025-09-28 2025-12-02 吉林大学 一种用于卵巢癌初步筛查的试剂盒及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776729A (en) * 1995-06-05 1998-07-07 Human Genome Sciences, Inc. Human G-protein receptor HGBER32
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
US7342108B2 (en) * 1998-06-25 2008-03-11 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
JP4315301B2 (ja) 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 ヒトＨ３７タンパク質と、このタンパク質をコードする ｃＤＮＡ
US6680197B2 (en) * 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
GB0119473D0 (en) 2001-08-09 2001-10-03 Astrazeneca Compounds
EP1425393A4 (en) * 2001-08-21 2005-08-17 Millennium Pharm Inc SEARCH FOR CDC7 INHIBITORS
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
CA2524528A1 (en) * 2003-05-05 2004-11-18 Pharmacia Italia S.P.A. Truncated forms of human dbf4, complexes with their interacting partners and methods for identification of inhibitors thereof
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005073374A1 (ja) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用
US8536313B2 (en) * 2007-07-10 2013-09-17 Shionogi & Co., Ltd. Monoclonal antibody having neutralizing activity against MMP13
RS54147B1 (sr) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
KR101351195B1 (ko) 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
DK2220245T3 (en) * 2007-10-17 2015-06-29 Univ Leland Stanford Junior Method and composition for the crystallization of G protein coupled receptors
WO2009123568A1 (en) 2008-03-31 2009-10-08 Agency For Science, Technology & Research High efficiency linear transmitter
TW201000115A (en) * 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
ITBO20090075A1 (it) * 2009-02-13 2010-08-14 Magneti Marelli Spa Macchina elettrica con singolo statore e due rotori tra loro indipendenti e veicolo stradale provvisto di tale macchina elettrica
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012048291A2 (en) * 2010-10-08 2012-04-12 Proteapex Therapeutics Llc Compositions and methods for inhibition of mmp:mmp-substrate interactions
ES2700514T3 (es) * 2011-02-01 2019-02-18 Genmab As Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74
WO2013039477A1 (en) 2011-09-12 2013-03-21 University Of South Alabama Non-invasive methods of detecting target molecules
US9221876B2 (en) 2011-11-11 2015-12-29 Cardiovax, Llc Methods for treating kidney disease with fragments of ApoB-100
US9254311B2 (en) * 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9500651B2 (en) 2012-08-15 2016-11-22 Université de Montréal Method for identifying novel minor histocompatibility antigens
ES2774931T3 (es) * 2012-09-14 2020-07-23 Us Health Receptores de linfocitos t que reconocen MAGE-A3 restringida al MHC de clase II
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
WO2015092710A1 (en) * 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3446119A1 (en) * 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Similar Documents

Publication Publication Date Title
JP2018532382A5 (enExample)
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
JP2013521789A5 (enExample)
AR121587A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
JP2019513005A5 (enExample)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
CA2799934C (en) Respiratory syncytial virus antigenic compositions and methods
JP2015525217A5 (enExample)
JP2020506690A5 (enExample)
JP2019537424A5 (enExample)
JP2016527875A5 (enExample)
JP2019536426A5 (enExample)
JP2013517783A5 (enExample)
JP2010534463A5 (enExample)
JP2017538401A5 (enExample)
JP2016519932A5 (enExample)
JP2015509707A5 (enExample)
JP2018528237A5 (enExample)
JP2010516713A5 (enExample)
JP2012516140A5 (enExample)
IL294059A (en) Mutant rsv f protein and its use
JP2019530441A5 (enExample)
JP2015524422A5 (enExample)
JP2019520038A5 (enExample)